CPATA Patent Knowledge common mistakes
CPATA Patent Knowledge · Understand the traps and how to avoid them.
Treating the Canadian novelty grace period as a general one-year bar like the US, and assuming any disclosure by the inventor within 12 months is protected without checking the statutory conditions and the exceptions for third-party disclosure.
Candidates carry over US-style thinking from study materials or prior practice. Section 28.2(1) of the Patent Act gives a limited grace period only for disclosure by the applicant or by a person who obtained the subject matter from the applicant, and the exceptions in 28.2(2) and (3) (e.g., disclosure at a recognized exhibition or by a person who did not know and could not reasonably have known) are narrow. The interaction with the claim date and with disclosures in other jurisdictions is easy to misapply.
What to do instead
Build a decision tree: identify the claim date first, then ask who disclosed, when, and how. Memorize that the grace period runs from the claim date, not the filing date, and that it is measured differently from the US system. Practice with fact patterns where a co-inventor, a licensee, or a conference presentation is the disclosing party, and where a third party independently discloses the same invention.
Drafting claims that read on a method of medical treatment or on a mere scientific principle or abstract theorem, then defending them as patentable subject matter without redrafting into an eligible format (e.g., a use claim, a dosage regime framed as a use, or a physical composition).
Candidates conflate US eligibility doctrine (Alice/Mayo) with Canadian law, or forget that Canadian practice permits use claims and 'Swiss-type'-style formats but not methods of surgery or therapy on a living subject. The Amazon.com one-click decision and the push to claim computer-implemented inventions also create confusion about what is 'statutory' under section 2.
What to do instead
Memorize the categories: methods of medical treatment are not patentable, but use claims and claims to a physical article or a computer-implemented process with a tangible effect may be. Practice converting a method-of-treatment disclosure into a use claim and a dosing-regime claim. Review the CIPO practice guidance on computer-implemented inventions and the statutory definition of 'invention' in section 2.
Missing the Canadian due-care and request-for-examination deadlines, or assuming that paying a maintenance fee late without the prescribed surcharge or reinstatement procedure preserves the application.
The Patent Rules set out a sequence of notices (the requisition for examination, the notice of non-compliance, the final action) and specific response periods, and candidates often memorize the US or PCT timelines instead. Maintenance fees are due annually on the filing anniversary, and late payment triggers a surcharge and, if unpaid, deemed abandonment with a reinstatement window that has its own fee and timing rules.
What to do instead
Create a one-page timeline for a Canadian application: filing, request for examination (with the current deadline), the examiner's requisition, the response period, the final action, the appeal to the Patent Appeal Board, and the maintenance-fee cycle. Practice calculating dates from a hypothetical filing date and cross-check against the current Patent Rules, since the rules were substantially amended in 2019 and the numbers have changed.
Filing a PCT application and then entering the Canadian national phase without checking the 30-month deadline, the translation requirements, and whether the applicant is entitled to the priority claim, and without paying the national-phase fee in the right window.
Candidates treat PCT national phase as automatic and uniform across countries. Canada has its own entry requirements, including the 30-month period from the priority date (extendable in limited circumstances), a copy of the international application and any amendments, and payment of the national fee. Errors in the priority claim or in the applicant's identity can be fatal or require correction under the Rules.
What to do instead
Work through a PCT national-phase checklist for Canada: confirm the 30-month date, confirm the priority claim and any restoration of priority, confirm the applicant and inventor declarations, confirm translation of the international application if not in English or French, and confirm payment of the basic national fee and any late fees. Practice a scenario where the 30-month deadline is missed and identify the available remedies.
Analyzing obviousness only with the US Graham factors or only with the 'obvious to try' test, without applying the Canadian approach that considers the common general knowledge, the inventive step, and the 'obvious to try' factors from the Sanofi decision in a structured way.
Candidates memorize a list of factors without understanding which are dispositive. Canadian courts apply the Windsurfing/Pozzoli framework as adopted in Sanofi, and the 'obvious to try' analysis has specific factors (whether the route was obvious, the extent of effort, the predictability of the art). Candidates also forget that the standard is the notional skilled person at the claim date with the common general knowledge, not the inventor's actual path.
What to do instead
Practice writing a full obviousness analysis using the four-step framework: identify the skilled person and common general knowledge, identify the inventive concept, identify the differences, and ask whether those differences were obvious. Then apply the 'obvious to try' factors explicitly. Compare with a fact pattern where the invention was the result of routine experimentation versus one requiring unexpected selection.
Drafting a specification that satisfies the US best-mode and written-description standards but fails Canadian sufficiency and the 'sound prediction' requirement for utility, especially for pharmaceutical and biotech claims.
Canadian law requires the specification to describe the invention and its operation or use in such full, clear, concise, and exact terms as to enable a person skilled in the art to make and use it. Utility is a requirement, and for compounds whose utility is not demonstrated, the sound-prediction doctrine requires a factual basis and a sound line of reasoning. Candidates trained on US practice underestimate how much Canadian examiners and courts demand in the specification.
What to do instead
For every claim, ask whether the specification provides an enabling disclosure and a credible basis for utility. For pharmaceutical cases, include data or a reasoned prediction with the factual basis and the reasoning. Practice identifying a claim that is broader than the disclosure and redrafting either the claim or the specification to close the gap.
Assuming that a Canadian patent can be enforced against a party who makes, uses, or sells the invention outside Canada, or that foreign activity is irrelevant to Canadian infringement analysis.
Infringement under the Patent Act is territorial. Candidates mix up the location of the infringing act with the location of the patentee, and they overlook that exporting a product made by a patented process from Canada, or inducing or contributing to infringement in Canada, can still be actionable. The 'extraterritorial' issue also arises with divided infringement and with products assembled abroad from Canadian-made components.
What to do instead
Map every claim element to a location and an actor. Ask whether each act of making, constructing, using, or selling occurred in Canada, and whether a party induced or procured infringement in Canada. Practice with a fact pattern involving a Canadian manufacturer exporting a kit and a foreign assembler, and identify which acts are actionable and which are not.
Treating an assignment or licence as effective against third parties without recording it, and misstating who owns an invention made by an employee in the absence of a written agreement.
Candidates assume that a signed assignment automatically binds the world, or that an employer owns an employee's invention by default. In Canada, the default rule is that an employee owns inventions made in the course of employment unless the employment contract or the nature of the duties implies otherwise, and recordal of assignments and licences with CIPO affects the ability to deal with the patent and to sue. The distinction between assignment and licence, and between exclusive and non-exclusive licences, also matters for standing.
What to do instead
Memorize the default ownership rule and the factors courts use (duties of the employee, use of employer resources, express terms). Practice drafting an assignment clause, a licence clause, and a recordal request. For standing, check whether the plaintiff is the owner or an exclusive licensee and whether the assignment or licence was recorded.
Ignoring conflicts of interest and confidentiality duties when acting for multiple parties in a patent family, or when a former client's confidential information is relevant to a new matter, and failing to obtain informed consent or to decline the retainer.
Patent practice often involves inventors, assignees, licensees, and joint owners with divergent interests, and candidates underestimate how the professional conduct rules apply. The duty of loyalty and the duty of confidentiality survive the end of the retainer, and a joint retainer requires full disclosure and consent. Candidates also forget the duty of candour to the Office and the limits on communications with an unrepresented adverse party.
What to do instead
Before accepting a joint retainer, identify each party's interest, disclose the conflict, and obtain written consent or decline. Keep a conflicts check for every new matter, including former clients. Review the professional conduct rules on joint retainers, confidential information, and communications, and practice a scenario where an inventor and a company disagree about ownership.
Confusing the transitional provisions after the 2019 Patent Rules amendments and the 2019 amendments to the Patent Act, and applying the wrong version of a rule to an application filed before the change.
The 2019 changes introduced new examination deadlines, new fees, and changes to the treatment of divisional applications, among other things, and the transitional rules determine which version applies. Candidates study the current rules only and then misapply them to older applications, or they miss that certain provisions apply based on the filing date or the date of a request for examination.
What to do instead
Build a table of the key changes and their transitional triggers (filing date, examination request date, national-phase entry date). Practice a scenario with an application filed in 2015 and a divisional filed in 2020, and determine which deadlines and fees apply to each. Cross-check against the transitional provisions in the amending legislation.